AstraZeneca PLC ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $66.99
- Today's High:
- $67.6075
- Open Price:
- $67.16
- 52W Low:
- $51.8968
- 52W High:
- $76.56
- Prev. Close:
- $66.6
- Volume:
- 4309793
Company Statistics
- Market Cap.:
- $228.52 billion
- Book Value:
- 1.9177
- Revenue TTM:
- $43.84 billion
- Operating Margin TTM:
- 23.1%
- Gross Profit TTM:
- $35.73 billion
- Profit Margin:
- 10.73%
- Return on Assets TTM:
- 6.43%
- Return on Equity TTM:
- 13.05%
Company Profile
AstraZeneca PLC ADR had its IPO on 1993-05-12 under the ticker symbol AZN.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. AstraZeneca PLC ADR has a staff strength of 83,500 employees.
Stock update
Shares of AstraZeneca PLC ADR opened at $67.16 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $66.99 - $67.61, and closed at $67.34.
This is a +1.11% increase from the previous day's closing price.
A total volume of 4,309,793 shares were traded at the close of the day’s session.
In the last one week, shares of AstraZeneca PLC ADR have slipped by -1.17%.
AstraZeneca PLC ADR's Key Ratios
AstraZeneca PLC ADR has a market cap of $228.52 billion, indicating a price to book ratio of 6.2133 and a price to sales ratio of 4.6505.
In the last 12-months AstraZeneca PLC ADR’s revenue was $43.84 billion with a gross profit of $35.73 billion and an EBITDA of $14.89 billion. The EBITDA ratio measures AstraZeneca PLC ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, AstraZeneca PLC ADR’s operating margin was 23.1% while its return on assets stood at 6.43% with a return of equity of 13.05%.
In Q1, AstraZeneca PLC ADR’s quarterly earnings growth was a positive 365.2% while revenue growth was a negative 4.5%.
AstraZeneca PLC ADR’s PE and PEG Ratio
- Forward PE
- 18.4162
- Trailing PE
- 48.5828
- PEG
- 1.3764
Its diluted EPS in the last 12-months stands at $1.51 per share while it has a forward price to earnings multiple of 18.4162 and a PEG multiple of 1.3764. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AstraZeneca PLC ADR’s profitability.
AstraZeneca PLC ADR stock is trading at a EV to sales ratio of 5.3395 and a EV to EBITDA ratio of 28.1105. Its price to sales ratio in the trailing 12-months stood at 4.6505.
AstraZeneca PLC ADR stock pays annual dividends of $2.9 per share, indicating a yield of 1.98% and a payout ratio of 43.28%.
Balance sheet and cash flow metrics
- Total Assets
- $96.69 billion
- Total Liabilities
- $24.86 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.47 billion
- Dividend Payout Ratio
- 43.28%
AstraZeneca PLC ADR ended 2024 with $96.69 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $96.69 billion while shareholder equity stood at $35.79 billion.
AstraZeneca PLC ADR ended 2024 with $0 in deferred long-term liabilities, $24.86 billion in other current liabilities, 387000000.00 in common stock, $-1825000000.00 in retained earnings and $20.00 billion in goodwill. Its cash balance stood at $6.23 billion and cash and short-term investments were $6.46 billion. The company’s total short-term debt was $3,857,000,000 while long-term debt stood at $26.92 billion.
AstraZeneca PLC ADR’s total current assets stands at $22.27 billion while long-term investments were $0 and short-term investments were $230.00 million. Its net receivables were $10.29 billion compared to accounts payable of $19.21 billion and inventory worth $4.97 billion.
In 2024, AstraZeneca PLC ADR's operating cash flow was $0 while its capital expenditure stood at $1.47 billion.
Comparatively, AstraZeneca PLC ADR paid $0.43 in dividends in 2024.
Other key metrics
- Current Trading Price
- $67.34
- 52-Week High
- $76.56
- 52-Week Low
- $51.8968
- Analyst Target Price
- $79.43
AstraZeneca PLC ADR stock is currently trading at $67.34 per share. It touched a 52-week high of $76.56 and a 52-week low of $76.56. Analysts tracking the stock have a 12-month average target price of $79.43.
Its 50-day moving average was $68.23 and 200-day moving average was $68.94 The short ratio stood at 1.24 indicating a short percent outstanding of 0%.
Around 0.6% of the company’s stock are held by insiders while 1810.2% are held by institutions.
Frequently Asked Questions About AstraZeneca PLC ADR
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.